Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Automated microscopy and Spatial Proteomics
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Related topics
Theranostics: From Mice to Men and Back
Jun 25, 2024
Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert
Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma
Jun 21, 2024
RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...
Hypoxia in the Tumor Immune Microenvironment (TIME)
Jun 6, 2024
Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD
...
X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization
Jun 5, 2024
Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...
Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain
Jun 4, 2024
MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...
Exosome-Mediated Delivery of Small Molecules, RNA & DNA for Development of Novel Cancer Therapeutics
Jun 3, 2024
Disha Moholkar of University of Louisville's Gupta Lab
Tuesday, June 11, 2024, 6:30 PM...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
May 27, 2024
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
High-frequency Ultrasound System For Preclinical Imaging
May 13, 2024
The Prospect T1 is an innovative high-frequency ultrasound system designed specifically for in vivo preclinical imaging...
Dec 8, 2016
The use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have already adapted to the liquid environment in the patient and do not depend on a stromal cell compartment. Aim of this study was to develop a systematic approach for the in-vitro culture of MPEs to analyze the effect of chemotherapeutic as well as targeted drugs.
Methods: MPEs from patients with solid tumors were selected for this study. After morphological and molecular characterization, they were cultured in medium supplemented with patient-derived sterile-filtered effusion supernatant. Growth characteristics were monitored in real-time using the xCELLigence system. MPEs were treated with a targeted therapeutic (erlotinib) according to the mutational status or chemotherapeutics based on the recommendation of the oncologists. Results: We have established a robust system for the ex-vivo culture of MPEs and the application of drug tests in-vitro. The use of an antibody based magnetic cell separation system for epithelial cells before culture allowed treatment of effusions with only moderate tumor cell proportion. Experiments using drugs and drug-combinations revealed dose-dependent and specific growth inhibitory effects of targeted drugs.
Conclusions: We developed a new approach for the ex-vivo culture of MPEs and the application of drug tests in-vitro using real-time measuring of cell growth, which precisely reproduced the effect of clinically established treatments by standard chemotherapy and targeted drugs. This sets the stage for future studies testing agents against specific targets from genomic profiling of metastatic tumor cells and multiple drug-combinations in a personalized manner.
Related technologies: Real-time, label free cell analysis
Get more info
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com